Q3 results, MD-CEO re-appointment for 3 years, MOA and AOA amendments approved
DMCC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts more than Nifty Microcap 250 and 4.4 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved Q3 FY26 results with revenue of Rs 15,083 lakhs and net profit of Rs 616 lakhs. Nine-month net profit rose to Rs 1,967 lakhs from Rs 1,507 lakhs last year. MD and CEO Bimal Goculdas re-appointed for 3 years from April 2026 to March 2029, subject to shareholder approval. Board also approved amendments to the MOA and adoption of a new set of Articles of Association to align with the Companies Act 2013. Remuneration increase for Executive Director Operations Kuldeep Tiwari approved. Postal ballot will be sent to shareholders for these items.
CEO re-appointment signals continuity. MOA and AOA changes modernize governance and need shareholder approval via postal ballot.